 |
|
Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis
Chia-Ling Yu, Fu-Chi Yang, Szu-Nian Yang, Ping-Tao Tseng, Brendon Stubbs, Ta-Chuan Yeh, Chih-Wei Hsu, Dian-Jeng Li, Chih-Sung Liang
Psychiatry Investig. 2021;18(10):958-967. Published online 2021 Oct 8 DOI: https://doi.org/10.30773/pi.2021.0209
|
|
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Nicolas Singewald, Simone B. Sartori, Andreas Reif, Andrew Holmes
Neuropharmacology.2023; 226: 109418. CrossRef Are psychedelics the answer to chronic pain: A review of current literature
Nina I. Kooijman, Tim Willegers, Anke Reuser, Wim M. Mulleners, Cornelis Kramers, Kris C. P. Vissers, Selina E. I. van der Wal
Pain Practice.2023; 23(4): 447. CrossRef The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
Daniel A Kinderlehrer
International Medical Case Reports Journal.2023; Volume 16: 109. CrossRef The need for establishing best practices and gold standards in psychedelic medicine
Allison Feduccia, Gabby Agin-Liebes, Collin M. Price, Nicole Grinsell, Summer Paradise, David M. Rabin
Journal of Affective Disorders.2023; 332: 47. CrossRef Psilocybin in Palliative Care: An Update
Emily Whinkin, Moira Opalka, Conor Watters, Atara Jaffe, Sunil Aggarwal
Current Geriatrics Reports.2023; 12(2): 50. CrossRef Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred, Ole Jakob Storebø
Journal of Psychopharmacology.2023; 37(7): 649. CrossRef
|